1. Home
  2. EKSO vs TCRT Comparison

EKSO vs TCRT Comparison

Compare EKSO & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ekso Bionics Holdings Inc.

EKSO

Ekso Bionics Holdings Inc.

HOLD

Current Price

$4.67

Market Cap

7.7M

Sector

Health Care

ML Signal

HOLD

Logo Alaunos Therapeutics Inc.

TCRT

Alaunos Therapeutics Inc.

N/A

Current Price

$4.26

Market Cap

8.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EKSO
TCRT
Founded
2005
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
8.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EKSO
TCRT
Price
$4.67
$4.26
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$7.75
N/A
AVG Volume (30 Days)
315.9K
65.9K
Earning Date
10-28-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,749,000.00
$6,000.00
Revenue This Year
N/A
$5,680,500.00
Revenue Next Year
$54.65
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.73
$1.31
52 Week High
$14.97
$6.20

Technical Indicators

Market Signals
Indicator
EKSO
TCRT
Relative Strength Index (RSI) 51.75 69.16
Support Level $3.50 $3.23
Resistance Level $4.93 $3.52
Average True Range (ATR) 0.40 0.36
MACD 0.06 0.09
Stochastic Oscillator 81.25 85.37

Price Performance

Historical Comparison
EKSO
TCRT

About EKSO Ekso Bionics Holdings Inc.

Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.

About TCRT Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.

Share on Social Networks: